Takeda Spins Out Research Team into Neuroscience Startup

Takeda Pharmaceutical has spun out its 25-person neuroscience research team in Cambridge, U.K., joining with Lightstone Ventures to help launch Cerevance, a new company focused on developing new treatments for neurological and psychiatric disorders.Cerevance will be led by Mark Carlton, Ph.D., who until now has been president and CSO of Takeda Cambridge. The company’s resources include a portfolio of preclinical and clinical-stage drug programs, lab space, and access to a new technology created in the Howard Hughes Medical Institute laboratory of Nathaniel Heintz, Ph.D., at The Rockefeller University. Cerevance has been funded with $36 million—including $21.5 million in Series A financing from Takeda and Lightstone. Representatives from each will join Cerevance’s board. “With a well-capitalized, proven team and promising drug programs already underway, we hope to rapidly advance a pipeline…


Link to Full Article: Takeda Spins Out Research Team into Neuroscience Startup

Pin It on Pinterest

Share This

Join Our Newsletter

Sign up to our mailing list to receive the latest news and updates about homeAI.info and the Informed.AI Network of AI related websites which includes Events.AI, Neurons.AI, Awards.AI, and Vocation.AI

You have Successfully Subscribed!